Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | NQO2 | P16083 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393886 | 1.00 | MAPT (0.57) | MAPTL3MBTL1SLC2A1CRHR1KDM4E | |
| SCHEMBL1564603 | 0.86 | NQO2 (0.54) | MAPTSLC2A1KDM4ENQO2ALDH1A1 | |
| SCHEMBL29420526 | 0.86 | NQO2 (0.54) | MAPTSLC2A1KDM4ENQO2ALDH1A1 | |
| SCHEMBL26766431 | 0.84 | CRHR1 (0.58) | MAPTSLC2A1CRHR1KDM4ENQO2 | |
| SCHEMBL18535287 | 0.83 | KDM4E (0.59) | MAPTSLC2A1CRHR1KDM4ENQO2 | |
| SCHEMBL20552708 | 0.82 | MCHR1 (0.54) | SLC2A1KDM4ENQO2ALDH1A1SMN1; SMN2 | |
| SCHEMBL22320170 | 0.82 | BDKRB2 (0.46) | MAPTL3MBTL1SLC2A1CRHR1KDM4E | |
| SCHEMBL22689428 | 0.82 | BDKRB2 (0.67) | MAPTL3MBTL1SLC2A1CRHR1 | |
| SCHEMBL3046111 | 0.81 | MAPT (0.51) | MAPTL3MBTL1SLC2A1CRHR1HPGD | |
| SCHEMBL3063558 | 0.80 | NR4A2 (0.71) | MAPTL3MBTL1CRHR1KDM4ENR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391681-B2 | (R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases | PHARVARIS GMBH (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12312330-B2 | 1-((S)-1-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)ethyl)-imidazolidine-2,4-dione derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases | PHARVARIS GMBH (CH) | 2025-05-27 | — | — | US | disclosed |
| CN-113906018-B | Bradykinin B2 receptor antagonists | 法瓦里斯有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-113906020-B | Cyclic bradykinin B2 receptor antagonists | 法瓦里斯有限责任公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| EP-3983402-B1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2023-08-16 | — | — | EP | disclosed |
| EP-3956326-B1 | (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2023-06-28 | — | — | EP | disclosed |
| CN-111433196-B | Bradykinin B2 receptor antagonists and uses thereof | 法瓦里斯荷兰有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20220289730-A1 | (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| EP-3998259-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | Pharvaris Netherlands B.V. (NL) | 2022-05-18 | — | — | EP | disclosed |
| CN-101784533-A | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO KG | 2010-07-21 | — | — | CN | disclosed |
| US-7754735-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1549634-A1 | NOVEL SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003101981-A1 | NOVEL SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| EP-0387821-B1 | 2-Alkyl-4-arylmethylaminoquinolines, their use and medicines containing them | BASF AG (DE) | 1994-08-24 | — | — | EP | disclosed |
| US-5102892-A | Antisecretory agent for gastrointestinal disorders | BASF AKTIENGESELLSCHAFT (DE) | 1992-04-07 | — | — | US | disclosed |
| EP-0387821-A2 | 2-Alkyl-4-arylmethylaminoquinolines, their use and medicines containing them | BASF Aktiengesellschaft (DE) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312330-B2 | 1-((S)-1-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)ethyl)-imidazolidine-2,4-dione derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases | BDKRB2, BDKRB1, BRCA1 | MAPT 4266/4885L3MBTL1 2200/4885SLC2A1 1992/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | MAPT 4719/4885L3MBTL1 4455/4885SLC2A1 1590/4885 |
| US-12391681-B2 | (R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases | BDKRB2, BDKRB1, BRCA1 | MAPT 3390/4885L3MBTL1 2493/4885SLC2A1 2550/4885 |
| US-20220289730-A1 | (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | BDKRB2, BDKRB1, BRCA1 | MAPT 3390/4885L3MBTL1 2493/4885SLC2A1 2550/4885 |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | BDKRB2, BDKRB1, VIPR2 | MAPT 3606/4885L3MBTL1 4812/4885SLC2A1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.